Catalyst Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 31.49 USD (Jul 15, 2026, 4:00 PM EDT) · Market cap 3.85B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticoste...